Sep 12, 2023 / 07:35PM GMT
Vikram Purohit - Morgan Stanley, Research Division - Equity Analyst
Let's go ahead and get started. My name is Vikram Purohit. I'm one of the biotech analysts with the Morgan Stanley Research team, joined by my colleague from the EU Biopharma team, James Quigley. This is the fireside chat with Genmab.
Before we get started, I need to read a brief disclosure statement.
For all important disclosures, please see www.morganstanley.com/research disclosures. And for any questions, please see your Morgan Stanley sales representative.
With that, happy to have with me on the stage the team from Genmab. Thanks for joining us. Appreciate it.
James, I'll turn it over to you to kick off with some questions, and then we'll just go back and forth. And if there's questions from the audience, please let us know.
Questions and Answers:
James Patrick Quigley - Morgan Stanley, Research Division - Equity AnalystExcellent. I mean the biggest thing -- the